SARS-CoV-2: basic concepts, origin and treatment advances
- PMID: 34125824
- DOI: 10.24875/GMM.M21000524
SARS-CoV-2: basic concepts, origin and treatment advances
Abstract
The first cases of COVID-19, caused by the virus called SARS-CoV-2, were recorded in Wuhan, China, in December 2019; however, its transmission ability caused for the infection to be practically present throughout the world six months later. The origin of the virus appears to be zoonotic; it has been proposed that it comes from a bat and that it may have had an intermediate host that led to its introduction in the human population. SARS-CoV-2 is an enveloped virus, with a positive single-stranded RNA genome, and it binds to the angiotensin-converting enzyme, present in susceptible cells, to infect the human respiratory system. Although other coronaviruses have been previously known, they have not had the same impact, and, therefore, research on pharmacological treatments is not sufficiently developed to face the current challenge. Almost since the beginning of the epidemic, several molecules have been proposed for the treatment of infection; however, there is not yet a drug available with sufficient effectiveness for treatment. This review describes SARS-CoV-2 main characteristics, its replicative cycle, its possible origin and some advances in the development of antiviral treatments.
Los primeros casos de COVID-19, causada por el virus denominado SARS-CoV-2, se registraron en Wuhan, China, en diciembre de 2019; sin embargo, su capacidad de transmisión ocasionó que seis meses después la infección prácticamente estuviera presente en todo el mundo. El origen del virus parece ser zoonótico; se propone que proviene del murciélago y podría haber tenido un hospedero intermediario que llevó a su introducción en la población humana. SARS-CoV-2 es un virus envuelto, con genoma de ARN de cadena sencilla en sentido positivo y se ancla a la enzima convertidora de angiotensina, presente en las células susceptibles para infectar el sistema respiratorio de los humanos. Aunque previamente se han conocido otros coronavirus, no han tenido el mismo impacto, por lo que la investigación en tratamientos farmacológicos no tiene el desarrollo suficiente para afrontar el reto actual. Casi desde el comienzo de la epidemia se han propuesto moléculas para el tratamiento de la infección, sin embargo, aún no se cuenta con un fármaco con suficiente efectividad terapéutica. En esta revisión se describen las características principales de SARS-CoV-2, su ciclo replicativo, su posible origen y algunos avances en el desarrollo de tratamientos antivirales.
Keywords: COVID-19; Coronavirus; Emerging viruses; Neumonía; Pneumonia; SARS-CoV-2; Virus Emergentes; Zoonosis.
Copyright: © 2020 Permanyer.
Similar articles
-
Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.Cells. 2021 Apr 6;10(4):821. doi: 10.3390/cells10040821. Cells. 2021. PMID: 33917481 Free PMC article. Review.
-
Receptor utilization of angiotensin-converting enzyme 2 (ACE2) indicates a narrower host range of SARS-CoV-2 than that of SARS-CoV.Transbound Emerg Dis. 2021 May;68(3):1046-1053. doi: 10.1111/tbed.13792. Epub 2020 Sep 5. Transbound Emerg Dis. 2021. PMID: 32794346 Free PMC article.
-
The novel zoonotic COVID-19 pandemic: An expected global health concern.J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671. J Infect Dev Ctries. 2020. PMID: 32235085
-
Advances in research on ACE2 as a receptor for 2019-nCoV.Cell Mol Life Sci. 2021 Jan;78(2):531-544. doi: 10.1007/s00018-020-03611-x. Epub 2020 Aug 11. Cell Mol Life Sci. 2021. PMID: 32780149 Free PMC article. Review.
-
Coronavirus biology and replication: implications for SARS-CoV-2.Nat Rev Microbiol. 2021 Mar;19(3):155-170. doi: 10.1038/s41579-020-00468-6. Epub 2020 Oct 28. Nat Rev Microbiol. 2021. PMID: 33116300 Free PMC article. Review.
Cited by
-
What we know and what we need to know about the origin of SARS-CoV-2.Environ Res. 2021 Sep;200:111785. doi: 10.1016/j.envres.2021.111785. Epub 2021 Jul 28. Environ Res. 2021. PMID: 34329631 Free PMC article.
-
Mesenchymal Stem Cell-Based Therapies in the Post-Acute Neurological COVID Syndrome: Current Landscape and Opportunities.Biomolecules. 2023 Dec 20;14(1):8. doi: 10.3390/biom14010008. Biomolecules. 2023. PMID: 38275749 Free PMC article. Review.
-
A Comprehensive Survey on the Expediated Anti-COVID-19 Options Enabled by Metal Complexes-Tasks and Trials.Molecules. 2023 Apr 10;28(8):3354. doi: 10.3390/molecules28083354. Molecules. 2023. PMID: 37110587 Free PMC article. Review.
-
Exploring TRIM proteins' role in antiviral defense against influenza A virus and respiratory coronaviruses.Front Cell Infect Microbiol. 2024 Jul 15;14:1420854. doi: 10.3389/fcimb.2024.1420854. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39077432 Free PMC article. Review.
-
Shedding light on the cell biology and diverse physiological functions of the migrasome.Cell Biosci. 2025 May 28;15(1):70. doi: 10.1186/s13578-025-01417-7. Cell Biosci. 2025. PMID: 40437622 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous